REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists unleash engineered virus to hunt down blood cancers
Disease control Recruiting nowThis early-stage trial is testing a new treatment for patients whose blood cancers have returned or not responded to standard therapies. The treatment uses a modified virus that is designed to selectively infect and kill cancer cells while sparing healthy ones. Researchers are st…
Matched conditions: REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
First-in-Human trial tests 'Off-the-Shelf' immune cells to fight aggressive blood cancers
Disease control Recruiting nowThis early-stage study is testing a new combination treatment for adults with specific types of T-cell lymphoma that have returned or not responded to prior therapy. The treatment involves giving patients immune cells from a healthy donor (called natural killer or NK cells) along…
Matched conditions: REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: John Reneau • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC